Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acadia Pharmaceutica
(NQ:
ACAD
)
15.94
+0.26 (+1.66%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Acadia Pharmaceutica
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic
January 18, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday
December 29, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Deep Dive Into ACADIA Pharmaceuticals Stock: Analyst Perspectives (13 Ratings)
December 29, 2023
Via
Benzinga
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
December 21, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Analyst Ratings for ACADIA Pharmaceuticals
December 12, 2023
Via
Benzinga
What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
November 06, 2023
Via
Benzinga
Analyst Ratings for ACADIA Pharmaceuticals
October 10, 2023
Via
Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 18, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)
December 13, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Soars To A Four-Month High After Winning A Patent Battle For Its Biggest Drug
December 13, 2023
MSN Labs lost out in a summary judgement to knock off Acadia's Nuplazid.
Via
Investor's Business Daily
Topics
Intellectual Property
Exposures
Intellectual Property
Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation
December 13, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Why Acadia Pharmaceuticals Stock Is Rising Today
October 10, 2023
An analyst upgrade is sparking a rally in the drugmaker's shares today.
Via
The Motley Fool
What's Going On With Acadia Pharmaceuticals Stock?
December 13, 2023
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares are trading higher Wednesday after the company won summary judgement in a patent suit regarding its Nuplazid drug. What To Know:
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 13, 2023
Via
Benzinga
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Leading the Way in Wednesday Trading Based on Percentage Gain
December 13, 2023
Via
Investor Brand Network
ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
December 11, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome
November 30, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
November 27, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Change in Research and Development Leadership
November 21, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 14, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
3 Biotech Stocks With the Strongest Clinical Pipelines
November 08, 2023
Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.
Via
InvestorPlace
Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
November 02, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
November 02, 2023
Via
Benzinga
Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference
October 31, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program
October 23, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023
October 19, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
October 17, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023
October 10, 2023
Via
Benzinga
Electronic Arts To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Tuesday
October 10, 2023
JP Morgan increased ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) price target from $29 to $32. JP Morgan analyst Tessa Romero upgraded the stock from Neutral to Overweight. ACADIA Pharmaceuticals shares...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.